Table 2 Causes for switching antifibrotics in first-line treatment and causes for discontinuation of second-line antifibrotics
First-line treatment (n = 37) [Pirfenidone (n = 29), Nintedanib (n = 8)] | Second-line treatment (n = 37) Nintedanib (n = 29), Pirfenidone (n = 8) | ||
|---|---|---|---|
Disease progression | 17 (45.9%), [2, 15] | Gastrointestinal side effects | 4 (5.4%), [1, 3] |
Gastrointestinal disorders | 12 (32.4%), [3, 9] | Rash | 1 (2.7%), [1, 0] |
Photosensitivity | 2 (5.4%), [2, 0] | Rash and dizziness | 1 (2.7%), [0, 1] |
Liver enzyme elevation | 2 (5.4%), [1, 1] | Dizziness | 1 (2.7%), [1, 0] |
Peripheral eosinophilia | 1 (2.7%), [1, 0] | Gastrointestinal perforation | 1 (2.7%), [1, 0] |
Lung cancer development | 1 (2.7%), [1, 0] | ||
Vasospastic angina suspected | 1 (2.7%), [0, 1] | ||
Patients’ will | 1 (2.7%), [1, 0] | ||